Allist Pharmaceuticals, Inc.
Clinical trials sponsored by Allist Pharmaceuticals, Inc., explained in plain language.
-
New hope for lung cancer patients with brain tumors
Disease control Recruiting nowThis international Phase 3 trial is testing whether a new drug, furmonertinib, works better when combined with standard chemotherapy compared to the current standard drug, osimertinib, for patients with a specific type of lung cancer that has spread to the brain. The study aims t…
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New lung cancer pill enters first human trials
Disease control Recruiting nowThis is the first study in people testing a new oral medication called AST2303 for advanced non-small cell lung cancer. The main goals are to find a safe dose, understand how the body processes the drug, and look for early signs that it might help shrink tumors. The study will en…
Phase: PHASE1 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for lung cancer patients: targeted therapy trial challenges standard chemotherapy
Disease control Recruiting nowThis study compares a new targeted drug called firmonertinib against standard chemotherapy for people with advanced non-small cell lung cancer who have specific genetic changes (EGFR PACC or L861Q mutations). About 300 participants will be randomly assigned to receive either the …
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC